Photopheresis
ICD-10-PCS6A650ZZ[note 1]
ICD-999.88
MeSHD017893

In medicine, photopheresis (aka extracorporeal photopheresis or ECP)[1] is a form of apheresis and photodynamic therapy in which blood is subject to apheresis to separate buffy coat (WBC + platelets) from whole blood, chemically treated with 8-methoxypsoralen (instilled into a collection bag or given per os in advance), exposed to ultraviolet light (UVA), and then returned to the patient.[2] Activated 8-methoxypsoralen crosslinks DNA in exposed cells, ultimately resulting apoptosis of nucleated cells.[1] The photochemically damaged T-cells returned to the patient appear to induce cytotoxic effects on T-cell formation. The mechanism of such “antitumor” action has not been elucidated.

A 1987 New England Journal of Medicine publication introduced photopheresis involving 8-methoxypsoralen.[1][3], now standard U.S. Food and Drug Administration (FDA) therapy for cutaneous T-cell lymphoma. Evidence suggests that this treatment might help treat graft-versus-host disease, though this evidence is largely observational; controlled trials are needed to support this use.[4][5] Photopheresis has also been successful in treating epidermolysis bullosa acquisita when all other treatments have been ineffective.[6]

Minimal observed side effects for patients receiving photopheresis include hypotension and syncope resulting from volume shifts during leukapheresis phase of treatment. Photopheresis is also an experimental treatment for patients with cardiac, pulmonary and renal allograft rejection, graft-versus-host disease, autoimmune diseases, nephrogenic systemic fibrosis and ulcerative colitis.

See also

Notes

  1. ↑ ICD10 Procedure code: this was assigned based on cross-walking from the ICD9 code at ICD10DAta.com

References

  1. 1 2 3 Klassen, J (2010). "The role of photopheresis in the treatment of graft-versus-host disease". Current Oncology. 17 (2): 55–8. doi:10.3747/co.v17i2.565. PMC 2854639. PMID 20404979.Open access icon
  2. ↑ "National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4)". Medicare Coverage Database. Centers for Medicare and Medicaid Services. 30 April 2012. Item/Service Description. 100-3.
  3. ↑ Edelson, R; Berger, C; Gasparro, F; Jegasothy, B; Heald, P; Wintroub, B; Vonderheid, E; Knobler, R; Wolff, K; Plewig, G; McKiernan, Glynis; Christiansen, Inger; Oster, Martin; Honigsmann, Hubert; Wilford, Hubert; Kokoschka, Eva; Rehle, Thomas; Perez, Maritza; Stingl, George; Laroche, Liliane (1987). "Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results". New England Journal of Medicine. 316 (6): 297–303. doi:10.1056/NEJM198702053160603. PMID 3543674.Closed access icon
  4. ↑ Buder, Kathrin; Zirngibl, Matthias; Bapistella, Sascha; Meerpohl, Joerg J.; Strahm, Brigitte; Bassler, Dirk; Weitz, Marcus (2022-06-09). "Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents". The Cochrane Database of Systematic Reviews. 6: CD009898. doi:10.1002/14651858.CD009898.pub4. ISSN 1469-493X. PMC 9181448. PMID 35679154.
  5. ↑ Buder, Kathrin; Zirngibl, Matthias; Bapistella, Sascha; Meerpohl, Joerg J.; Strahm, Brigitte; Bassler, Dirk; Weitz, Marcus (2022-09-27). "Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents". The Cochrane Database of Systematic Reviews. 9: CD009759. doi:10.1002/14651858.CD009759.pub4. ISSN 1469-493X. PMC 9514720. PMID 36166494.
  6. ↑ Gupta, R; Woodley, D. T.; Chen, M (2012). "Epidermolysis bullosa acquisita". Clinics in Dermatology. 30 (1): 60–9. doi:10.1016/j.clindermatol.2011.03.011. PMC 3234994. PMID 22137228.Open access icon

Further reading

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.